Press Coverage
Sofinnova Crossover
Tom Burt, partner at Sofinnova Partners, speaks at Edison Group’s Open House Global Healthcare Event
Related Strategy
CrossoverTom Burt, partner at Sofinnova Partners, joined Edison Group’s Open House Global Healthcare Event. His panel discussed some of the scenarios that are likely to play out in 2022 for biotech in public and private equity markets and M&A. View the replay here.
Related News
Hemab Therapeutics closes $347M Nasdaq IPO
CellCentric raises $220M Series D for inobrodib trials
Hemab Therapeutics prices IPO at $18 per share
Abivax announces full year 2025 financial results and provides business updates
Sensorion reports six-month update from the Audiogene Phase 1/2 Trial of SENS-501 and advances GJB2-GT (SENS-601) toward first-in-human clinical development